Design of a Commercial Scale Accelerator Driven Subcritical Aqueous Assembly
- SHINE Medical Technologies, 2555 Industrial Drive, Madison, WI, 53713 (United States)
SHINE Medical Technologies is working towards producing a reliable, domestic supply of medical isotopes, including molybdenum-99 (Mo-99), xenon-133, and iodine 131, without using highly enriched uranium. Approximately 88% of Mo-99 decays to technetium-99m, which is the most widely used medical isotope in the world, accounting for approximately 80% of all nuclear medicine procedures. A novel aqueous, subcritical nuclear assembly has been designed by SHINE Medical Technologies. The assembly can produce medical radioisotopes in significant quantities for U.S. and foreign needs. The assembly produces isotopes without using a reactor, instead using a fusion-based neutron source coupled to a fission-based aqueous assembly. The subcritical nature of the aqueous assembly has safety and licensing benefits, including the elimination of the reactor control system and elimination of high level waste. SHINE plans to construct eight subcritical assemblies with a plant capacity of greater than 3000 6-day Curies, which is more than one-quarter of the world's Mo-99 requirements. From a nuclear design standpoint, the aqueous subcritical assembly needs to be able to generate sufficient fission power to meet the production capacity requirements while remaining subcritical at all times with an acceptable margin. To address these conflicting design goals, a simple nuclear design and reactivity control philosophy has been developed that allows for high power operation with a high degree of safety. A fusion-driven subcritical fission assembly has been designed by SHINE Medical Technologies to provide a reliable, domestic supply of medical isotopes. Nuclear models have been created and show that the assembly can be started up, operated, and shutdown in a safe manner without active reactivity control systems. A unique reactivity control strategy allows SHINE to operate the aqueous subcritical assembly at much higher power levels than would otherwise be practical, while still retaining the benefits of subcritical operation and avoiding the need for complex subcritical measurement techniques. Based on the current design, the subcritical target is capable of generating significant fission power (on the order of 100 kW) when being driven by a simple, low-cost deuterium-tritium accelerator, enabling the SHINE facility to supply over one-fourth of the worldwide demand of Mo- 99. SHINE has recently been issued a construction permit by the U.S. Nuclear Regulatory Commission to build the commercial facility in Janesville, WI, with eight subcritical assemblies and the associated production equipment. (authors)
- OSTI ID:
- 22992007
- Journal Information:
- Transactions of the American Nuclear Society, Vol. 114, Issue 1; Conference: Annual Meeting of the American Nuclear Society, New Orleans, LA (United States), 12-16 Jun 2016; Other Information: Country of input: France; 3 refs.; Available from American Nuclear Society - ANS, 555 North Kensington Avenue, La Grange Park, IL 60526 United States; ISSN 0003-018X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Medical Isotope Production Analyses In KIPT Neutron Source Facility
Design of the Universal Neutron Irradiator
Related Subjects
97 MATHEMATICAL METHODS AND COMPUTING
ACCELERATORS
CONSTRUCTION PERMITS
GLOBAL ASPECTS
HIGH-LEVEL RADIOACTIVE WASTES
HIGHLY ENRICHED URANIUM
IODINE 131
MOLYBDENUM 99
NEUTRON SOURCES
NUCLEAR MEDICINE
NUCLEAR MODELS
REACTIVITY
REACTOR CONTROL SYSTEMS
SAFETY
SUBCRITICAL ASSEMBLIES
TECHNETIUM 99
XENON 133